AstraZeneca Launches 30000-Patient Phase III US Trial of COVID-19 Vaccine


He said the safest way for the vaccine to be available for use before the end of Phase Three trials, which involve thousands of patients and can take years, would be by issuing an emergency authorization for use by certain groups rather than a blanket approval, the FT reported.

The company said that the agreement could be extended by a further 18 months into 2022 and 2023 by mutual agreement.

AstraZeneca's goal is to involve 30,000 people in 80 USA locations over two years to investigate how the vaccine works and how safe it is, according to a Tuesday, Sept. 1 news release.

Results from the late-stage trials are anticipated later this year, depending on the rate of infection within the clinical trial communities, AstraZeneca said.

US President Donald Trump on Monday announced AstraZeneca's COVID-19 vaccine has reached Phase 3 clinical trials in the United States and is very close to being finalised for approval.

Developed in partnership with Oxford University, AZD1222 employs the husk of an inactivated virus to deliver genetic material. The much-needed thing of an hour is the potential COVID-19 vaccine.

AstraZeneca also restated that it has increased its production capacity for AZD1222 toward 3 billion doses of the vaccine, citing supply announcements covering Russia, South Korea, Japan, China, Latin America, and Brazil.

RNC Played Leonard Cohen's 'Hallelujah' Despite Being Denied
After that denial, the RNC also reached out to Sony/ATV Music Publishing to play the song. Christopher Macchio subsequently sang an operatic version as well.

Oxford University led the first phases of the trial.

The trial is being conducted under US government's Operation Warp Speed program, which aims to accelerate development, manufacturing and distribution of vaccines and treatments for COVID-19.

In addition to the U.S. Phase III trial, BARDA also agreed to fund another trial created to evaluate the vaccine in children.

There are now over 25 potential vaccine candidates in clinical trials around the world, according to the World Health Organisation.

AZD1222 is seen as one of the leading hopes among dozens of coronavirus vaccine candidates in development around the world.

The trial is funded by the Biomedical Advanced Development Authority, which is run by the US Department of Health and Human Services and the National Institute of Allergy and Infectious Diseases.